A new study in collaboration with Universitätsklinikum Hamburg-Eppendorf (UKE) and CTC North GmbH & Co. KG has been approved by the German Gemeinsamer Bundesausschuss (G-BA) on December 4. The G-BA has commissioned the UKE to research the benefits of allogeneic stem cell transplantation to treat multiple myeloma in relapsed/progressive patients. The project is led by principal investigator Prof. Dr. Nicolaus Kröger of UKE. Staburo GmbH is responsible for the statistical analysis. More information can be found in the press release of the G-BA (https://www.g-ba.de/presse/pressemitteilungen/917/).
INSIGHTS: Patient Data that Keeps Advancing Medicine
Every clinical trial dataset represents people who volunteered their time, energy, and health information in the hope of advancing medicine. That contribution doesn't have to end when a study report is finalised. When shared responsibly, anonymised individual patient...



